BCD-178

DRUG2 trials

Sponsors

Biocad

Conditions

Breast Cancer

Phase 1

A Double-Blind, Comparative, Randomized Clinical Study of the Pharmacokinetics, Safety, and Immunogenicity of a Single Intravenous Infusion of BCD-178 or Perjeta® in Healthy Volunteers

BiocadBreast Cancer

Start: 2022-08-08End: 2024-01-31Updated: 2023-02-22

Phase 3

Clinical Study of the Efficacy and Safety of BCD-178 and Perjeta® as Neoadjuvant Therapy of HER2-Positive Breast Cancer

Active, not recruitingNCT05802225

BiocadBreast Cancer

Start: 2023-01-30End: 2026-02-20Updated: 2025-07-20

Related Papers

Efficacy and safety of the pertuzumab biosimilar BCD-178 versus the originator pertuzumab in patients with HER2-positive locally advanced breast cancer: Results from the international, double-blind, randomized, phase III PREFER trial.

Journal of Clinical Oncology2026-05-27